News Room

Status COVID-19 Flu Background Image, Nurse and Patients

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

| Chembio | No Comments
Apr 1, 2021: In-licensed Rapid Point-of-Care Test Available for Use in Detecting COVID-19 Antigens, Flu A and Flu B from a Single Patient Sample in 15 Minutes Chembio Diagnostics, Inc. (Nasdaq: CEMI),…
David W. Bespalko

Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors

| Chembio | No Comments
Mar 8, 2021 HAUPPAUGE, N.Y., (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to the Company’s Board of Directors,…

Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems

| Chembio | No Comments
Jan 14, 2021 Enters Exclusive U.K. and Ireland Distribution Agreement with Luas Diagnostics HAUPPAUGE, N.Y., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases,…

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors

| Chembio | No Comments
HAUPPAUGE, N.Y., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company’s Board of Directors.…
DPP SARS-CoV-2 Antigen System

Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System

| Chembio | No Comments
HAUPPAUGE, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and…

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

| Chembio | No Comments
Nov 13, 2020 HAUPPAUGE, N.Y. (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received…
DPP SARS-CoV-2 Antigen System

Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

| Chembio | No Comments
Oct 15, 2020: Rapid Test Provides Results in Only 20 Minutes HAUPPAUGE, N.Y., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced…

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

| Chembio | No Comments
Oct 2, 2020: First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample HAUPPAUGE, N.Y., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI),…
DPP Microreader 2

Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System

| Chembio | No Comments
Sept. 08, 2020: New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous Whole Blood, Plasma, or Serum Samples HAUPPAUGE, N.Y., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI),…